Arthritis News and Research

Latest Arthritis News and Research

U.S. study finds improved mortality outcomes for children with rheumatic diseases

A recent study by researchers from the Cleveland Clinic found that the overall mortality rate in the U.S. for all pediatric patients with rheumatic diseases was not worse than the age and sex-adjusted population.

28 Jan 2010

Elevated cytokine levels are early indicator of rheumatoid arthritis

Researchers from University Hospital in Umea, Sweden, have identified several cytokines, cytokine-related factors, and chemokines that increase significantly prior to rheumatoid arthritis (RA) disease onset. These findings confirm those of earlier studies which suggest that the risk of developing RA can be predicted and disease progression may be prevented.

28 Jan 2010

UC-CCHMC partnership receives $3.75M NIAMS grant for musculoskeletal soft tissue repair research

An award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) will aid a partnership between the University of Cincinnati (UC) and Cincinnati Children's Hospital Medical Center (CCHMC) in finding new ways to use adult stem cells to speed repair of musculoskeletal soft tissue injuries.

28 Jan 2010

Abbott declares quarterly dividend of 40 cents per share

Abbott today announced financial results for the fourth quarter ended Dec. 31, 2009.

27 Jan 2010

Exactech to fund more than $100,000 in research and residency enhancement grants through OREF's CDP

Exactech Inc., a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today that the company has committed more than $100,000 to fund research and residency enhancement grants and contribute to post-graduate fellowship grants through OREF’s Clinician Development Program (CDP).

27 Jan 2010

Regular exercise associated with greater longevity and reduced risk of age-related conditions

Physical activity appears to be associated with a reduced risk or slower progression of several age-related conditions as well as improvements in overall health in older age, according to a commentary and four articles published in the January 25 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

27 Jan 2010

Tel Aviv University expert reviews environmental triggers of common autoimmune diseases

The links between autoimmune diseases, infections, genetics and the environment are complex and mysterious. Why are people who live near airports more susceptible to autoimmune diseases like rheumatoid arthritis and lupus? How do hormones in meat trigger the onset of a disease?

27 Jan 2010

Osiris Therapeutics completes enrollment in Prochymal MSC therapy Phase II trial for type 1 diabetes

Osiris Therapeutics, Inc. today announced that it has achieved a $750,000 milestone payment from the Juvenile Diabetes Research Foundation (JDRF) for completing enrollment in a Phase II clinical trial evaluating Prochymal, an adult mesenchymal stem cell (MSC) therapy, as a treatment for patients recently diagnosed with type 1 diabetes. The milestone is the fourth in a series of payments resulting from JDRF’s partnership with Osiris for the development of a therapy for type 1 diabetes.

27 Jan 2010

LTW Technologies' LED LIGHTWAVE therapy device receives 5 FDA clearances

LTW Technologies has received 5 FDA clearances (K082586) for its proprietary and unique multi-wavelength LED LIGHTWAVE therapy device. The LIGHTWAVE DELUXE series utilizes a revolutionary light therapy combination of Red light therapy, Blue light therapy and Infrared light therapy.

25 Jan 2010

Biogen Idec and Swedish Orphan Biovitrum commence dosing in rFIXFc Phase I/IIa trial for hemophilia B

Biogen Idec and Swedish Orphan Biovitrum today announced that the first patient was dosed in a registrational, open-label, multicenter trial designed to evaluate the safety, pharmacokinetics and efficacy of the companies’ long-acting, recombinant Factor IX Fc fusion protein (rFIXFc) in hemophilia B patients.

25 Jan 2010

Loss of key proteins may account for molecular abnormalities associated with myotonic dystrophy

Research on the genetic defect that causes myotonic muscular dystrophy has revealed that the mutation disrupts an array of metabolic pathways in muscle cells through its effects on two key proteins.

24 Jan 2010

Biogen Idec's statement on FDA approval of AMPYRA

Biogen Idec today issued the following statement regarding the United States (U.S.) Food and Drug Administration (FDA) approval of AMPYRA™ (dalfampridine) to improve walking in patients with multiple sclerosis (MS).

23 Jan 2010

MACI/ACI therapies could prevent total joint replacement in OA patients

Osteoarthritis (OA) is one of the ten most disabling diseases in the developed world and is set to become more of a financial burden on health services as average life expectancy increases.

23 Jan 2010

Mice study shows obesity can increase risk of developing liver cancer

Obesity comes with plenty of health risks, but there's one that's perhaps not so well known: an increased risk of developing cancer, and especially certain types of cancer like liver cancer. Now, a group of researchers reporting in the January 22nd issue of the journal Cell, a Cell Press publication, have confirmed in mice that obesity does indeed act as a "bona fide tumor promoter." They also have good evidence to explain how that happens.

22 Jan 2010

Scientific/technical review for XIAFLEX' European MAA commences

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced that its partner Auxilium Pharmaceuticals, Inc. announced that Pfizer Inc. received notification from the European Medicines Agency that the Marketing and Authorization Application (MAA) for XIAFLEX™ for the treatment of Dupuytren's disease (a debilitating disorder resulting from excessive collagen deposition that causes contractures of the fingers) has completed the validation phase successfully and that the scientific/technical review procedure commenced today.

21 Jan 2010

Amgen announces results of two Phase 3 studies evaluating Vectibix for mCRC

Amgen today announced that detailed results from two pivotal Phase 3 studies evaluating Vectibix® (panitumumab) in combination with chemotherapy for the first and second-line treatment of metastatic colorectal cancer (mCRC) (the PRIME '203' and '181' trials, respectively) will be presented at the 2010 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in Orlando, Florida from Jan. 22-24, 2010.

21 Jan 2010

Abaxis' new CRP assay receives FDA marketing clearance

Abaxis, Inc., a medical products company manufacturing point-of-care blood analysis systems, today announced that the U.S. Food and Drug Administration (FDA) has granted 510K marketing clearance of the new C-Reactive Protein (CRP) assay when used by healthcare professionals in conjunction with the Piccolo Xpress™ point-of-care analyzer.

21 Jan 2010

Dosing in First-in-Man Phase I study of 4SC AG's 4SC-203 commenced

4SC AG, a drug discovery and development company, today announced the start of dosing in a First-in-Man Phase I study in healthy volunteers evaluating 4SC-203, a novel multi-target kinase inhibitor, with particular specificity against selected kinases, including FMS-like tyrosine kinase 3 (FLT3), FLT3 mutants and vascular endothelial growth factor receptors (VEGF-R).

21 Jan 2010

Research shows brain abnormalities develop years before Parkinson's symptoms appear

Scientists who have identified brain networks damaged in Parkinson's disease have new evidence that these systems become abnormal a few years before symptoms appear. And what's more, parts of the network appear to respond in a last ditch attempt to rescue the brain.

21 Jan 2010

VisEn Medical announces the commercial launch of new Cat B 680 FAST imaging agent

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new Cat B 680 FAST™ imaging agent for measuring and monitoring cathepsin B activity associated with disease progression and therapeutic response in vivo.

21 Jan 2010

Arthritis News and Research

Latest Arthritis News and Research

U.S. study finds improved mortality outcomes for children with rheumatic diseases

Elevated cytokine levels are early indicator of rheumatoid arthritis

UC-CCHMC partnership receives $3.75M NIAMS grant for musculoskeletal soft tissue repair research

Abbott declares quarterly dividend of 40 cents per share

Exactech to fund more than $100,000 in research and residency enhancement grants through OREF's CDP

Regular exercise associated with greater longevity and reduced risk of age-related conditions

Tel Aviv University expert reviews environmental triggers of common autoimmune diseases

Osiris Therapeutics completes enrollment in Prochymal MSC therapy Phase II trial for type 1 diabetes

LTW Technologies' LED LIGHTWAVE therapy device receives 5 FDA clearances

Biogen Idec and Swedish Orphan Biovitrum commence dosing in rFIXFc Phase I/IIa trial for hemophilia B

Loss of key proteins may account for molecular abnormalities associated with myotonic dystrophy

Biogen Idec's statement on FDA approval of AMPYRA

MACI/ACI therapies could prevent total joint replacement in OA patients

Mice study shows obesity can increase risk of developing liver cancer

Scientific/technical review for XIAFLEX' European MAA commences

Amgen announces results of two Phase 3 studies evaluating Vectibix for mCRC

Abaxis' new CRP assay receives FDA marketing clearance

Dosing in First-in-Man Phase I study of 4SC AG's 4SC-203 commenced

Research shows brain abnormalities develop years before Parkinson's symptoms appear

VisEn Medical announces the commercial launch of new Cat B 680 FAST imaging agent

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Arthritis News and Research

Latest Arthritis News and Research

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Newsletters you may be interested in